Terumo Corporation Receives FDA Clearances for Medis QFR 3.0 and Carotid Stent System
Terumo Corporation, a health care equipment and supply manufacturer, has received FDA clearances for two new products. The company has obtained clearance for its Medis QFR 3.0 software, a coronary physiology assessment tool that utilizes AI technology. The software aims to enhance catheterization laboratory efficiency and patient comfort.
The Medis QFR 3.0 software was developed in collaboration with Medis Medical Imaging. This clearance marks a notable achievement for Terumo Health Outcomes, a division of the company.
In a separate development, Terumo Neuro, a subsidiary of the company, has secured FDA approval for its Carotid Stent System. The Carotid Stent System is a dual-layer micromesh carotid stent, which is a first-of-its-kind product.
Product Details
- Medis QFR 3.0 software:
- Utilizes AI technology
- Enhances catheterization laboratory efficiency and patient comfort
- Carotid Stent System:
- Dual-layer micromesh carotid stent
- First-of-its-kind product
Company Commitment
These developments demonstrate Terumo’s commitment to delivering innovative solutions that improve patient outcomes and enhance the efficiency of healthcare services.